Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Pfizer Inc./Seagen Inc. merger agreement
| March 12, 2023 • Antitrust Risk-shifting • $43 billion (including net debt; enterprise value). |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.